COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 342.0 | 9 | 0042-0526 | 480.04 | 525.65 | 299 | 66.77 | 0.843 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 304.2 | 9 | 0043-0560 | 241.00 | 560.24 | 284 | 66.77 | 0.801 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 269.6 | 9 | 0044-0582 | 19.55 | 581.95 | 287 | 64.53 | 0.866 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 390.0 | 9 | 0045-0581 | 306.88 | 581.25 | 226 | 58.18 | 0.839 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 350.3 | 9 | 0046-0596 | 783.57 | 595.75 | 266 | 63.84 | 0.820 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 348.8 | 9 | 0047-0601 | 698.86 | 601.44 | 250 | 62.53 | 0.804 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 302.9 | 9 | 0048-0605 | 942.34 | 604.53 | 260 | 67.01 | 0.728 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 275.4 | 9 | 0049-0613 | 300.09 | 612.81 | 325 | 66.43 | 0.926 |
COLO 858 | Vemurafenib | 3.16 | uM | 48 | hr | | | Cycle-1 | H3 (pS10) | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | H3 (pS10) | | 284.6 | 9 | 0050-0664 | 878.63 | 665.31 | 280 | 63.60 | 0.870 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1583.0 | 1 | 0001-0030 | 113.89 | 29.84 | 299 | 67.60 | 0.822 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1957.3 | 1 | 0002-0029 | 168.91 | 28.72 | 294 | 66.18 | 0.843 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 2376.2 | 1 | 0003-0033 | 263.30 | 34.12 | 210 | 55.36 | 0.861 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1552.2 | 1 | 0004-0039 | 463.46 | 39.70 | 310 | 65.36 | 0.912 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1565.4 | 1 | 0005-0040 | 504.82 | 41.10 | 293 | 68.67 | 0.781 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1547.8 | 1 | 0006-0040 | 720.01 | 40.44 | 289 | 75.74 | 0.633 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 4106.2 | 1 | 0007-0041 | 803.55 | 41.85 | 444 | 87.50 | 0.729 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 2085.5 | 1 | 0008-0042 | 418.82 | 41.04 | 267 | 61.11 | 0.898 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 3556.2 | 1 | 0009-0042 | 87.75 | 42.02 | 158 | 48.63 | 0.840 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 2481.3 | 1 | 0010-0045 | 289.33 | 45.56 | 376 | 71.94 | 0.913 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 3423.4 | 1 | 0011-0044 | 589.42 | 44.68 | 234 | 56.28 | 0.928 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 692.5 | 1 | 0012-0045 | 693.34 | 45.35 | 223 | 54.87 | 0.931 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 3616.2 | 1 | 0013-0042 | 652.67 | 42.21 | 177 | 52.63 | 0.803 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 4012.3 | 1 | 0014-0047 | 771.72 | 47.09 | 254 | 59.36 | 0.906 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 3486.5 | 1 | 0015-0051 | 172.16 | 51.15 | 276 | 61.94 | 0.904 |
COLO 858 | Vemurafenib | 0 | uM | 48 | hr | | | Cycle-2 | Rb (pS807; pS811); Rb (pS807); Rb (pS811) / clone D20B12 / Alexa Fluor 555 | rabbit IgG(H+L) / goat / cross-adsorbed | Cy3 | Rb (pS807; pS811) | | 1997.0 | 1 | 0016-0050 | 534.61 | 50.03 | 323 | 66.77 | 0.910 |